112 related articles for article (PubMed ID: 26740452)
1. Severe toxicity of chemotherapy against advanced soft tissue sarcoma in Werner's syndrome: Ifosfamide-induced encephalopathy with central diabetes insipidus.
Tsukamoto S; Kurematsu Y; Honoki K; Kido A; Somekawa S; Kaya D; Sadamitsu T; Fukui H; Tanaka Y
J Orthop Sci; 2016 May; 21(3):403-6. PubMed ID: 26740452
[No Abstract] [Full Text] [Related]
2. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
[TBL] [Abstract][Full Text] [Related]
3. Mesna, Doxorubicin, Ifosfamide and Dacarbazine (MAID) Combination Chemotherapy for Retroperitoneal Sarcoma: A Single-center Experience.
Ishiyama Y; Inakawa T; Yoshino M; Nishimura K; Horiuchi T; Ishihara H; Toki D; Kondo T
Anticancer Res; 2024 Jul; 44(7):3213-3220. PubMed ID: 38925814
[TBL] [Abstract][Full Text] [Related]
4. Optimizing clinical care in patients with advanced soft tissue sarcoma: a phase II study of a new schedule of high-dose continuous infusion ifosfamide and doxorubicin combination.
De Pas T; Rosati G; Spitaleri G; Boni C; Tucci A; Frustaci S; Scalamogna R; Radice D; Boselli S; Toffalorio F; Catania C; Noberasco C; Delmonte A; Vecchio F; de Braud F
Chemotherapy; 2011; 57(3):217-24. PubMed ID: 21597285
[TBL] [Abstract][Full Text] [Related]
5. Advances in chemotherapy for patients with extremity soft tissue sarcoma.
Eilber FC; Tap WD; Nelson SD; Eckardt JJ; Eilber FR
Orthop Clin North Am; 2006 Jan; 37(1):15-22. PubMed ID: 16311108
[TBL] [Abstract][Full Text] [Related]
6. Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy.
Barişta I; Tekuzman G; Yalçin S; Güllü I; Güler N; Ozişik Y; Kars A; Celik I; Türker A; Altundağ K; Zengin N; Uner A; Baltali E; Firat D
J Surg Oncol; 2000 Jan; 73(1):12-6. PubMed ID: 10649272
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas.
Nielsen OS; Reichardt P; Christensen TB; Pink D; Daugaard S; Hermans C; Marreaud S; van Glabbeke M; Blay J; Judson I
Eur J Cancer; 2006 Sep; 42(14):2303-9. PubMed ID: 16891112
[TBL] [Abstract][Full Text] [Related]
8. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas.
Le Cesne A; Antoine E; Spielmann M; Le Chevalier T; Brain E; Toussaint C; Janin N; Kayitalire L; Fontaine F; Genin J
J Clin Oncol; 1995 Jul; 13(7):1600-8. PubMed ID: 7541449
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Santoro A; Tursz T; Mouridsen H; Verweij J; Steward W; Somers R; Buesa J; Casali P; Spooner D; Rankin E
J Clin Oncol; 1995 Jul; 13(7):1537-45. PubMed ID: 7602342
[TBL] [Abstract][Full Text] [Related]
10. [Preliminary result of advanced soft tissue sarcoma treated by MAID regimen].
Huang YH; Wen XP; Hu L
Ai Zheng; 2002 Aug; 21(8):907-9. PubMed ID: 12478905
[TBL] [Abstract][Full Text] [Related]
11. Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults.
Fiegl M; Schlemmer M; Wendtner CM; Abdel-Rahman S; Fahn W; Issels RD
Int J Hyperthermia; 2004 Sep; 20(6):661-70. PubMed ID: 15370821
[TBL] [Abstract][Full Text] [Related]
12. Alternating sequential chemotherapy with high-dose ifosfamide and doxorubicin/cyclophosphamide for adult non-small round cell soft tissue sarcomas.
Kawai A; Umeda T; Wada T; Ihara K; Isu K; Abe S; Ishii T; Sugiura H; Araki N; Ozaki T; Yabe H; Hasegawa T; Tsugane S; Beppu Y;
J Orthop Sci; 2005 May; 10(3):258-63. PubMed ID: 15928887
[TBL] [Abstract][Full Text] [Related]
13. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma.
Schütte J; Mouridsen HT; Steward W; Santoro A; van Oosterom AT; Somers R; Blackledge G; Verweij J; Dombernowsky P; Thomas D
Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S204-9. PubMed ID: 8453699
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant therapy for resectable high-risk soft tissue sarcoma: feasibility and efficacy of a sandwich chemoradiotherapy strategy.
Brandts CH; Schulz C; Willich N; Steffen B; Hardes J; Gosheger G; Winkelmann W; Serve H; Heinecke A; Berdel WE; Thomas M
Cancer Chemother Pharmacol; 2012 Mar; 69(3):613-20. PubMed ID: 21947168
[TBL] [Abstract][Full Text] [Related]
16. High-dose-intensity combination chemotherapy for advanced sarcomas: a pilot study.
Pronzato P; Losardo P; Pensa F; Tognoni A
Cancer Chemother Pharmacol; 1998; 41(6):513-6. PubMed ID: 9554597
[TBL] [Abstract][Full Text] [Related]
17. Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous-infusion etoposide.
Saeter G; Talle K; Solheim OP
Cancer Chemother Pharmacol; 1995; 36(2):172-5. PubMed ID: 7539339
[TBL] [Abstract][Full Text] [Related]
18. Low dose adriamycin and ifosfamide in the treatment of advanced adult soft tissue sarcomas.
Comandone A; Bretti S; Bertetto O; Oliva C; Bergnolo P; Bumma C
Anticancer Res; 2000; 20(3B):2077-80. PubMed ID: 10928155
[TBL] [Abstract][Full Text] [Related]
19. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas.
Eilber FC; Rosen G; Eckardt J; Forscher C; Nelson SD; Selch M; Dorey F; Eilber FR
J Clin Oncol; 2001 Jul; 19(13):3203-9. PubMed ID: 11432887
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
